Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Austin Biosciences-1103
- Development stage
- Preclinical
- Lead developer
- Austin Biosciences
- Modality
- Small Molecules
- Administration
- Injectable
01
Overview
**Austin Biosciences-1103** is a preclinical-stage drug candidate from Austin Biosciences Corp., leveraging a proprietary nanotechnology-based drug delivery platform to enhance the therapeutic index of existing FDA-approved cancer therapies. It improves bioavailability, solubility, and efficacy while reducing toxicity by enabling active targeting of cancer cells, including those across the blood-brain barrier. Developed using LASSN™ technology, it focuses on reformulating active pharmaceutical ingredients (APIs) for oncology indications, with a planned Phase 1 trial initiation in Q1 2024 or earlier.[7][9][13]
Beyond the preview
Go deeper on Austin Biosciences-1103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Austin Biosciences-1103.